Statistical analysis
Toxicity
Safety and efficacy were evaluated in all patients enrolled who received at least one dose of elranatamab. Elranatamab dose escalation was guided using a Bayesian method with modified Toxicity Probability Interval designSummary statistics for categorical variables were reported with mean (s.d.) or median (95% CI or range) unless otherwise specified. Time-to-event endpoints were analyzed using the Kaplan–Meier method